nitrates has been researched along with Diabetic Nephropathies in 19 studies
Nitrates: Inorganic or organic salts and esters of nitric acid. These compounds contain the NO3- radical.
Diabetic Nephropathies: KIDNEY injuries associated with diabetes mellitus and affecting KIDNEY GLOMERULUS; ARTERIOLES; KIDNEY TUBULES; and the interstitium. Clinical signs include persistent PROTEINURIA, from microalbuminuria progressing to ALBUMINURIA of greater than 300 mg/24 h, leading to reduced GLOMERULAR FILTRATION RATE and END-STAGE RENAL DISEASE.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Urinary samples with positive (at least one +) proteinuria, hematuria, leucocyturia, or nitrates using the Multistix strip were excluded from the study." | 3.71 | Interest of Clinitek Microalbumin in screening for microalbuminuria: results of a multicentre study in 302 diabetic patients. ( Le Floch, JP; Marre, M; Passa, P; Rodier, M, 2001) |
| "Diabetes complications included congestive heart failure, coronary heart disease, angina, stroke, myocardial infarction, diabetic retinopathy, and nephropathy." | 1.91 | Association of Urinary Nitrate With Diabetes Complication and Disease-Specific Mortality Among Adults With Hyperglycemia. ( Han, T; Jiang, W; Liu, S; Ma, L; Sun, C; Sun, X; Wei, W; Wu, H; Yang, R; Zhang, J, 2023) |
| "The best treatment for coronary artery disease (CAD) in patients with type 2 diabetes (DM2) and chronic kidney disease is unknown." | 1.62 | Effect of diabetic kidney disease on therapeutic strategies for coronary artery disease: ten year follow-up. ( Batista, DV; Filho, JPPL; Filho, RK; Garcia, RMR; Garzillo, CL; Hueb, W; Junior, CVS; Lima, EG; Martins, EB; Ramires, JAF; Rezende, PC, 2021) |
| "Diabetic nephropathy was exacerbated drastically by a nitric oxide synthase inhibitor and mildly by a NO precursor." | 1.33 | Chronic inhibition of nitric oxide production aggravates diabetic nephropathy in Otsuka Long-Evans Tokushima Fatty rats. ( Higuchi, M; Hora, K; Kamijo, H, 2006) |
| "Renal biopsies from patients with diabetic nephropathy (DM), acute allograft rejection (AAR), acute allograft tubular necrosis (ATN), and glomerulonephritis (GN) were obtained." | 1.31 | Increased nitrotyrosine staining in kidneys from patients with diabetic nephropathy. ( Dodd, SM; Nott, CA; Thuraisingham, RC; Yaqoob, MM, 2000) |
| "The rats with diabetic acute renal failure had a much lower creatinine clearance (90 +/- 22 microliters." | 1.29 | Nitric oxide in ischaemic acute renal failure of streptozotocin diabetic rats. ( Blum, M; Cabili, S; Chernihovsky, T; Goor, Y; Iaina, A; Peer, G; Silverberg, D; Wollman, Y, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (10.53) | 18.2507 |
| 2000's | 11 (57.89) | 29.6817 |
| 2010's | 4 (21.05) | 24.3611 |
| 2020's | 2 (10.53) | 2.80 |
| Authors | Studies |
|---|---|
| Jiang, W | 1 |
| Zhang, J | 2 |
| Yang, R | 1 |
| Sun, X | 1 |
| Wu, H | 1 |
| Liu, S | 1 |
| Sun, C | 1 |
| Ma, L | 1 |
| Han, T | 1 |
| Wei, W | 1 |
| Batista, DV | 1 |
| Hueb, W | 1 |
| Lima, EG | 1 |
| Rezende, PC | 1 |
| Garzillo, CL | 1 |
| Garcia, RMR | 1 |
| Filho, JPPL | 1 |
| Martins, EB | 1 |
| Junior, CVS | 1 |
| Ramires, JAF | 1 |
| Filho, RK | 1 |
| Singh, L | 1 |
| Arya, A | 1 |
| Gupta, S | 1 |
| You, H | 1 |
| Gao, T | 1 |
| Cooper, TK | 1 |
| Morris, SM | 1 |
| Awad, AS | 1 |
| Morsy, MA | 1 |
| Heeba, GH | 1 |
| Mahmoud, ME | 1 |
| Okada, S | 1 |
| Saito, M | 1 |
| Kazuyama, E | 1 |
| Hanada, T | 1 |
| Kawaba, Y | 1 |
| Hayashi, A | 1 |
| Satoh, K | 1 |
| Kanzaki, S | 1 |
| Imanishi, M | 1 |
| Okada, N | 1 |
| Konishi, Y | 1 |
| Morikawa, T | 1 |
| Maeda, I | 1 |
| Kitabayashi, C | 1 |
| Masada, M | 1 |
| Shirahashi, N | 1 |
| Wilcox, CS | 1 |
| Nishiyama, A | 1 |
| Bhatia, S | 1 |
| Shukla, R | 1 |
| Venkata Madhu, S | 1 |
| Kaur Gambhir, J | 1 |
| Madhava Prabhu, K | 1 |
| Hiragushi, K | 2 |
| Wada, J | 2 |
| Eguchi, J | 1 |
| Matsuoka, T | 1 |
| Yasuhara, A | 1 |
| Hashimoto, I | 1 |
| Yamashita, T | 1 |
| Hida, K | 1 |
| Nakamura, Y | 1 |
| Shikata, K | 2 |
| Minamino, N | 1 |
| Kangawa, K | 1 |
| Makino, H | 2 |
| Kamijo, H | 1 |
| Higuchi, M | 1 |
| Hora, K | 1 |
| Bassand, JP | 1 |
| Hamm, CW | 1 |
| Ardissino, D | 1 |
| Boersma, E | 1 |
| Budaj, A | 1 |
| Fernández-Avilés, F | 1 |
| Fox, KA | 1 |
| Hasdai, D | 1 |
| Ohman, EM | 1 |
| Wallentin, L | 1 |
| Wijns, W | 1 |
| Goor, Y | 1 |
| Peer, G | 1 |
| Iaina, A | 1 |
| Blum, M | 1 |
| Wollman, Y | 1 |
| Chernihovsky, T | 1 |
| Silverberg, D | 1 |
| Cabili, S | 1 |
| Sugimoto, H | 1 |
| Matsuda, M | 1 |
| Kushiro, M | 1 |
| Hayashi, Y | 1 |
| Thuraisingham, RC | 1 |
| Nott, CA | 1 |
| Dodd, SM | 1 |
| Yaqoob, MM | 1 |
| Chiarelli, F | 1 |
| Cipollone, F | 1 |
| Romano, F | 1 |
| Tumini, S | 1 |
| Costantini, F | 1 |
| di Ricco, L | 1 |
| Pomilio, M | 1 |
| Pierdomenico, SD | 1 |
| Marini, M | 1 |
| Cuccurullo, F | 1 |
| Mezzetti, A | 1 |
| Le Floch, JP | 1 |
| Marre, M | 1 |
| Rodier, M | 1 |
| Passa, P | 1 |
| De Vriese, AS | 1 |
| Stoenoiu, MS | 1 |
| Elger, M | 1 |
| Devuyst, O | 1 |
| Vanholder, R | 1 |
| Kriz, W | 1 |
| Lameire, NH | 1 |
| Trachtman, H | 1 |
| Futterweit, S | 1 |
| Pine, E | 1 |
| Mann, J | 1 |
| Valderrama, E | 1 |
| Wang, H | 1 |
| Deng, H | 1 |
| Liu, W | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Non-interventional Study to Estimate the Rates of Outcomes in ACS Patients in Moscow[NCT03654157] | 1,576 participants (Actual) | Observational | 2018-03-25 | Completed | |||
| Rivaroxaban Evaluation in Real Life Settings[NCT02444221] | 5,278 participants (Actual) | Observational [Patient Registry] | 2015-07-01 | Completed | |||
| Analgesia of Acute Coronary Syndromes With ST-segment Elevation in a Pre-hospital Setting. Randomized Non-inferiority Trial of the Association MEOPA + Paracetamol Versus Morphine.[NCT02198378] | Phase 4 | 680 participants (Actual) | Interventional | 2014-11-30 | Completed | ||
| Reduction of Ischemic Myocardium With Ranolazine-Treatment in Patients With Acute Myocardial Ischemia[NCT01797484] | Phase 2/Phase 3 | 20 participants (Actual) | Interventional | 2013-08-31 | Completed | ||
| Effect of RAS Inhibitors on Albuminuria, Hyperfiltration and Endothelial Dysfunction in a Sickle Cell Disease Population.[NCT01195818] | 53 participants (Actual) | Interventional | 2010-09-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Relativ acceleration or deceleration (1/s) of left ventricular myocardial sections compared to direct opposite section. The more positive the value, the more simultaneously the movements, the more hemodynamically better. (NCT01797484)
Timeframe: 42 days after first dose of Ranolazine
| Intervention | percentage of change (Mean) |
|---|---|
| Ranolazine | 18 |
| No Additional Medication | 23 |
1 trial available for nitrates and Diabetic Nephropathies
| Article | Year |
|---|---|
Angiotensin II receptor blockade reduces salt sensitivity of blood pressure through restoration of renal nitric oxide synthesis in patients with diabetic nephropathy.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Albuminuria; Angiotensin Receptor Antagonists; Biopterins; Blood Pressu | 2013 |
18 other studies available for nitrates and Diabetic Nephropathies
| Article | Year |
|---|---|
Association of Urinary Nitrate With Diabetes Complication and Disease-Specific Mortality Among Adults With Hyperglycemia.
Topics: Adult; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus; Diabetic Nephropathies; H | 2023 |
Effect of diabetic kidney disease on therapeutic strategies for coronary artery disease: ten year follow-up.
Topics: Aged; Aspirin; Calcium Channel Blockers; Coronary Artery Disease; Diabetes Mellitus, Type 2; Diabeti | 2021 |
Role of atrial natriuretic peptide in controlling diabetic nephropathy in rats.
Topics: Adenine; Animals; Atrial Natriuretic Factor; Blood Glucose; Diabetes Mellitus, Experimental; Diabeti | 2018 |
Diabetic nephropathy is resistant to oral L-arginine or L-citrulline supplementation.
Topics: Amino Acids; Animals; Arginase; Arginine; Blood Pressure; Citrulline; Diabetes Mellitus, Experimenta | 2014 |
Ameliorative effect of eprosartan on high-fat diet/streptozotocin-induced early diabetic nephropathy in rats.
Topics: Acrylates; Angiotensin II; Animals; Blood Glucose; Catalase; Cholesterol; Collagen Type IV; Diabetic | 2015 |
Effects of N-hexacosanol on nitric oxide synthase system in diabetic rat nephropathy.
Topics: Animals; Diabetic Nephropathies; Fatty Alcohols; Gene Expression Regulation, Enzymologic; Immunoblot | 2008 |
Antioxidant status, lipid peroxidation and nitric oxide end products in patients of type 2 diabetes mellitus with nephropathy.
Topics: Antioxidants; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Erythrocytes; Female; Glutathione; | 2003 |
The role of adrenomedullin and receptors in glomerular hyperfiltration in streptozotocin-induced diabetic rats.
Topics: Adrenomedullin; Animals; Aorta; Blood Glucose; Blotting, Northern; Cells, Cultured; Diabetes Mellitu | 2004 |
Chronic inhibition of nitric oxide production aggravates diabetic nephropathy in Otsuka Long-Evans Tokushima Fatty rats.
Topics: Animals; Arginine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Enzyme Inhibitors; Kidney Glom | 2006 |
Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes.
Topics: Adrenergic beta-Antagonists; Anemia; Angioplasty, Balloon, Coronary; Anticoagulants; Biomarkers; Blo | 2007 |
Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes.
Topics: Adrenergic beta-Antagonists; Anemia; Angioplasty, Balloon, Coronary; Anticoagulants; Biomarkers; Blo | 2007 |
Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes.
Topics: Adrenergic beta-Antagonists; Anemia; Angioplasty, Balloon, Coronary; Anticoagulants; Biomarkers; Blo | 2007 |
Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes.
Topics: Adrenergic beta-Antagonists; Anemia; Angioplasty, Balloon, Coronary; Anticoagulants; Biomarkers; Blo | 2007 |
Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes.
Topics: Adrenergic beta-Antagonists; Anemia; Angioplasty, Balloon, Coronary; Anticoagulants; Biomarkers; Blo | 2007 |
Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes.
Topics: Adrenergic beta-Antagonists; Anemia; Angioplasty, Balloon, Coronary; Anticoagulants; Biomarkers; Blo | 2007 |
Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes.
Topics: Adrenergic beta-Antagonists; Anemia; Angioplasty, Balloon, Coronary; Anticoagulants; Biomarkers; Blo | 2007 |
Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes.
Topics: Adrenergic beta-Antagonists; Anemia; Angioplasty, Balloon, Coronary; Anticoagulants; Biomarkers; Blo | 2007 |
Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes.
Topics: Adrenergic beta-Antagonists; Anemia; Angioplasty, Balloon, Coronary; Anticoagulants; Biomarkers; Blo | 2007 |
Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes.
Topics: Adrenergic beta-Antagonists; Anemia; Angioplasty, Balloon, Coronary; Anticoagulants; Biomarkers; Blo | 2007 |
Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes.
Topics: Adrenergic beta-Antagonists; Anemia; Angioplasty, Balloon, Coronary; Anticoagulants; Biomarkers; Blo | 2007 |
Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes.
Topics: Adrenergic beta-Antagonists; Anemia; Angioplasty, Balloon, Coronary; Anticoagulants; Biomarkers; Blo | 2007 |
Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes.
Topics: Adrenergic beta-Antagonists; Anemia; Angioplasty, Balloon, Coronary; Anticoagulants; Biomarkers; Blo | 2007 |
Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes.
Topics: Adrenergic beta-Antagonists; Anemia; Angioplasty, Balloon, Coronary; Anticoagulants; Biomarkers; Blo | 2007 |
Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes.
Topics: Adrenergic beta-Antagonists; Anemia; Angioplasty, Balloon, Coronary; Anticoagulants; Biomarkers; Blo | 2007 |
Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes.
Topics: Adrenergic beta-Antagonists; Anemia; Angioplasty, Balloon, Coronary; Anticoagulants; Biomarkers; Blo | 2007 |
Nitric oxide in ischaemic acute renal failure of streptozotocin diabetic rats.
Topics: Acute Kidney Injury; Analysis of Variance; Animals; Arginine; Creatinine; Diabetes Mellitus, Experim | 1996 |
Increased expression of endothelial cell nitric oxide synthase (ecNOS) in afferent and glomerular endothelial cells is involved in glomerular hyperfiltration of diabetic nephropathy.
Topics: Animals; Arterioles; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Endothelium, Vascular; | 1998 |
Increased nitrotyrosine staining in kidneys from patients with diabetic nephropathy.
Topics: Adolescent; Adult; Aged; Child; Diabetic Nephropathies; Female; Humans; Immunohistochemistry; Kidney | 2000 |
Increased circulating nitric oxide in young patients with type 1 diabetes and persistent microalbuminuria: relation to glomerular hyperfiltration.
Topics: Adolescent; Adult; Albuminuria; Biomarkers; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 1 | 2000 |
Interest of Clinitek Microalbumin in screening for microalbuminuria: results of a multicentre study in 302 diabetic patients.
Topics: Albuminuria; Creatinine; Diabetes Mellitus; Diabetic Nephropathies; France; Hematuria; Hospitals, Un | 2001 |
Diabetes-induced microvascular dysfunction in the hydronephrotic kidney: role of nitric oxide.
Topics: Animals; Blood Vessels; Diabetes Mellitus, Experimental; Diabetic Angiopathies; Diabetic Nephropathi | 2001 |
Chronic diabetic nephropathy: role of inducible nitric oxide synthase.
Topics: Animals; Blood Glucose; Body Weight; Chronic Disease; Diabetic Nephropathies; Growth; Immunoblotting | 2002 |
[The effects of paraoxonase-1 and oxidized low density lipoprotein on nephropathy in type-2 diabetes mellitus].
Topics: Adult; Aryldialkylphosphatase; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Esterases; Female; | 2002 |